RT Journal Article
SR Electronic
T1 Evaluation of Tumor Response to Adjuvant Treatments using an Ex Vivo Culture of Breast Carcinoma Spheroids in a Microfluidic Device
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257378
DO 10.1101/2021.05.19.21257378
A1 Es, Hamidreza Aboulkheyr
A1 Aref, Amir Reza
A1 Granpayeh, Lobat
A1 Ebrahimi, Marzieh
A1 Baharvand, Hossein
YR 2021
UL http://medrxiv.org/content/early/2021/05/22/2021.05.19.21257378.abstract
AB Purpose Breast cancer is the leading cause of cancer-related death among women worldwide. Conventional chemotherapy is considered a clinical state of the art treatment; however, resistance or recurrence occurs among a considerable portion of these patients. Besides understanding the genomic alterations pattern of tumor cells and their association with drug resistance or response, the development of a reliable tumor models that reflect the major cellular and molecular features of tumors may aid with screening of candidate drugs and identification of appropriate treatment regimens. Here, we developed a simple and low-cost tumor model of breast cancer to screen library of chemotherapy agents in a pre-clinical setting.Methods we generated and cultured ex-vivo 3D culture of patient-derived tumor spheroids from both pre-treated primary and metastatic tumors using a partial digestion approach in a microfluidic device. We assessed chemotherapy response of the seven patient-derived breast tumor spheroids and expanded evaluation of drug sensitivity through molecular analysis of a small panel of genes.Results We observed various chemotherapy responses across primary and metastasis tumor samples. Interestingly, we demonstrated response to paclitaxel and doxorubicin and resistance to cisplatin in 2/3 metastatic tumor samples while most of the primary tumor were responsive to chemotherapy. Additionally, the expression of PIK3CA and loss of PTEN were associated to treatment resistance.Conclusion Our study suggests potential application of microfluidic-based cell culture technology coupled with patient derived tumor spheroids in prediction of treatment response in a personalized manner.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was founded by grants awarded by Royan Institute, and the Iran National Science Foundation (INSF), [Grant No. 96001316] to H.B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study procedures were conducted in accordance with the ethical standards approved by Royan Institute Ethical Committee (94000024) and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot available